Karla Fabiola Chacón-Vargas, Benjamin Nogueda-Torres, Luvia E Sánchez-Torres, Erick Suarez-Contreras, Juan Carlos Villalobos-Rocha, Yuridia Torres-Martinez, Edgar E Lara-Ramirez, Giulia Fiorani, R Luise Krauth-Siegel, Maria Laura Bolognesi, Antonio Monge, Gildardo Rivera
Molecules (Basel, Switzerland) 2017 Feb 01Chagas disease or American trypanosomiasis is a worldwide public health problem. In this work, we evaluated 26 new propyl and isopropyl quinoxaline-7-carboxylate 1,4-di-N-oxide derivatives as potential trypanocidal agents. Additionally, molecular docking and enzymatic assays on trypanothione reductase (TR) were performed to provide a basis for their potential mechanism of action. Seven compounds showed better trypanocidal activity on epimastigotes than the reference drugs, and only four displayed activity on trypomastigotes; T-085 was the lead compound with an IC50 = 59.9 and 73.02 µM on NINOA and INC-5 strain, respectively. An in silico analysis proposed compound T-085 as a potential TR inhibitor with better affinity than the natural substrate. Enzymatic analysis revealed that T-085 inhibits parasite TR non-competitively. Compound T-085 carries a carbonyl, a CF3, and an isopropyl carboxylate group at 2-, 3- and 7-position, respectively. These results suggest the chemical structure of this compound as a good starting point for the design and synthesis of novel trypanocidal derivatives with higher TR inhibitory potency and lower toxicity.
Karla Fabiola Chacón-Vargas, Benjamin Nogueda-Torres, Luvia E Sánchez-Torres, Erick Suarez-Contreras, Juan Carlos Villalobos-Rocha, Yuridia Torres-Martinez, Edgar E Lara-Ramirez, Giulia Fiorani, R Luise Krauth-Siegel, Maria Laura Bolognesi, Antonio Monge, Gildardo Rivera. Trypanocidal Activity of Quinoxaline 1,4 Di-N-oxide Derivatives as Trypanothione Reductase Inhibitors. Molecules (Basel, Switzerland). 2017 Feb 01;22(2)
PMID: 28157150
View Full Text